Patient P-01318

Synthetic patientNBL-101 · Day 116 · 45–54 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Stable

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

84%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 45 SC-12 recommended — Supportive Compound SC-12
Day 46 Patient accepted — Started SC-12 in the companion
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 GI symptom burden −15% vs expected — Supportive Compound SC-12
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 58 Tolerance state changed — Unstable → Improving
Day 63 GI symptom burden −34% vs expected — GI Support Protocol GI-04
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

GI instability+14
Inflammatory activity+8
Treatment adherence-8
Nutritional resilience-7
Toxicity-2

What helped?

Supportive Compound SC-12Day 45
Result: symptom burden −15%
GI Support Protocol GI-04Day 54
Result: symptom burden −34%

LIFE OS recommendation

Dietary Support Protocol NP-02

60%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

52.8/100

worsening · +1.7 vs previous 14 d

Toxicity

Blood

45.3/100

worsening · +6.4 vs previous 14 d

Sleep quality

Wearable

49.1/100

stable · -1.4 vs previous 14 d

Energy level

Daily log

2.3/10

worsening · -1.1 vs previous 14 d

Stress level

Daily log

6.6/10

worsening · +0.3 vs previous 14 d

Steps

Wearable

5,193

worsening · -423 vs previous 14 d

Adherence

Companion

46.1 %

worsening · -2.3 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 20 from the failing basin, 68 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 78 similar · onset 3 d · confidence 73%
NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 73%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 73%

Would not help

Keep histamine low
GI +5.1 next day on high-intake days · n 21
Keep simple carbs low
GI +4.7 next day on high-intake days · n 17
Keep fat low
GI +4.4 next day on high-intake days · n 26

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+5.1detractor · 95%
Simple carbohydrates
+4.7detractor · 95%
Dietary fat load
+4.4detractor · 95%
Insoluble fibre
+2.5detractor · 60%
Alcohol
-0.6no signal · 15%
Spicy / capsaicin
+0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑25
- BloodInflammatory load index 56
Autonomic recovery ↓25
- WearableResting HR 74 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 45

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.3 · butyrate capacity 23/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 57 ms
Sleep: 6.2 h
Steps: 5,103
Resting HR: 73 bpm

Daily log: GI score 53, nutritional resilience 37, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01750	22%	S16	—	—	69
P-01699	26%	S04	GI-04	improved	69
P-01509	22%	S17	—	—	68
P-01877	24%	S01	CR-01	improved	67
P-01629	22%	S19	—	—	66
P-01714	27%	S14	GI-04	improved	66
P-01858	29%	S14	NP-02	improved	65
P-01317	23%	S19	—	—	65
P-01643	22%	S17	—	—	65
P-01417	28%	S14	GI-04	improved	65
P-01511	28%	S14	GI-04	improved	65
P-01542	22%	S07	—	—	65